Serostatus refers to the presence or absence of a serological marker in the blood. The presence of detectable levels of a specific marker within the serum is considered seropositivity, while the absence of such levels is considered seronegativity.


The term serostatus is commonly used in HIV/AIDS prevention efforts. In the late 20th and early 21st centuries, social advocacy has emphasized the importance of learning one's HIV/AIDS serostatus in an effort to curtail the spread of the disease.[1]

Autoimmune disease

Researchers have investigated the effects of autoantibody serostatus on autoimmune disease presentation.[2][3][4] Study of seronegative patient populations has led to the identification of additional autoantibodies that could potentially help with diagnosis.[5][6]

See also


  1. ^ Janssen RS, Holtgrave DR, Valdiserri RO, et al. (July 2001). "The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals". American Journal of Public Health. American Public Health Association. 91 (7): 1019–1024. doi:10.2105/AJPH.91.7.1019. ISSN 1541-0048. PMC 1446705. PMID 11441723.
  2. ^ Jarius S, Ruprecht K, Wildemann B, et al. (January 2012). "Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients". Journal of Neuroinflammation. BioMed Central. 9 (1): 14. doi:10.1186/1742-2094-9-14. PMC 3283476. PMID 22260418.
  3. ^ Ajeganova S, Huizinga TW (November 2014). "Rheumatoid arthritis: Seronegative and seropositive RA: alike but different?". Nature Reviews Rheumatology. Nature Publishing Group. 11 (1): 8–9. doi:10.1038/nrrheum.2014.194. ISSN 1759-4804. PMID 25403158. S2CID 1405551.
  4. ^ Balasubramanian G, Sugumar A, Smyrk TC, et al. (2012). "Demystifying seronegative autoimmune pancreatitis". Pancreatology. Elsevier. 12 (4): 289–294. doi:10.1016/j.pan.2012.05.003. PMID 22898628.
  5. ^ Somers K, Geusens P, Elewaut D, et al. (February 2011). "Novel autoantibody markers for early and seronegative rheumatoid arthritis". Journal of Autoimmunity. Elsevier. 36 (1): 33–46. doi:10.1016/j.jaut.2010.10.003. ISSN 0896-8411. PMID 21071175.
  6. ^ Pevzner A, Schoser B, Peters K, et al. (August 2011). "Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis" (PDF). Journal of Neurology. Springer-Verlag. 259 (3): 427–435. doi:10.1007/s00415-011-6194-7. ISSN 1432-1459. PMID 21814823. S2CID 13125248.